2016 American Transplant Congress
Potential Applications of Viral miRNA Assays in the Management of Transplant Patients with Polyomavirus BK Infection.
Background: BKV encodes two miRNAs from a single precursor: BKV-miR-B1-5p & BKV-JCV-miR-BJ1-3p. These viral miRNAs direct cleavage of large T antigen mRNAs, downregulate viral T…2015 American Transplant Congress
Impact of Donor and Recipient BKV Serostatus and the Effect of Ciprofloxacin Prophylaxis on BK Viremia Risk After Kidney Transplant
Background: BK virus (BKV) is a common infection in kidney transplant recipients. Due to widespread latent BKV infection in the general population, it is possible…2015 American Transplant Congress
Switching from Tacrolimus to Low-Dose Cyclosporine A Preserves Allograft Function in Presumptive and Definitive Polyomavirus-Associated Nephropathy
Switching from tacrolimus(Tac) to low-dose cyclosporine A(CsA) is recommended for preventing BK virus-associated nephropathy(BKVAN) and preserving allograft function in BKVAN patients, but systematic evaluations were…2015 American Transplant Congress
T Cell Receptor Repertoire Analysis of BKV-Specific T Cells in Peripheral Blood Samples By Next Generation Sequencing Reveals Differential Role and Kinetics of CD4 and CD8 T Cell Clones in Viral Control
Background:BKV-specific T cells play the crucial role in controlling virus reactivation and analyses of their frequencies have been previously performed in different studies. However, nothing…2015 American Transplant Congress
A Prospective Pilot Study Evaluating the Safety and Efficacy of Everolimus for the Prevention of CMV and BK Viral Infection (BKV) in Broadly Sensitized Kidney Transplant Recipients Following Desensitization With IVIG and Rituximab: Interim Analysis
Introduction: Everolimus, a second generation mTOR inhibitor, may prevent CMV and BKV infection after kidney transplantation. Broadly sensitized patients are at greater risk of viral…2015 American Transplant Congress
Everolimus Conversion to Treat BK Virus Infection in Kidney Transplant Recipients
IntroductionmTORi's reduce BKV large T antigen expression in vitro and are associated with lower rates of BKV infection in clinical studies.MethodsPilot single center, randomized, open-label…2015 American Transplant Congress
Role of CMV, BKV, and Immunosupression Non-Adherence in Early and Late De Novo Donor Specific Anti-HLA Antibody Development and Outcomes
This analysis aims to identify appropriate de novo DSA (dnDSA) screening points and delineate the post-transplant (txp) scenarios preceding dnDSA development to aid in clinical…2015 American Transplant Congress
De Novo Donor Specific Antibody (DSA) After Treatment of BK Infection With Intravenous Immunoglobulin (IVIG)
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: The primary treatment for polyomavirus BK viral infection (BKV) is a reduction in immunosuppression exposure. However this can lead to rejection and development of…2015 American Transplant Congress
BK Virus-Specific Polyfunctional CD8+ T Cells Predicts Successful Control of BK Viremia After Kidney Transplantation
Introduction: BK Virus associated nephropathy (BKN) remains an important cause of graft loss after kidney transplantation. We hypothesized that analysis of the anti-BK virus immune…2015 American Transplant Congress
Safety and Efficacy of 3-Month Ciprofloxacin for BK Prophylaxis in Kidney Transplantation
Houston Methodist Hospital, Houston, TX.
Flouroquinolones(FQ) have been shown to inhibit BK virus (BKV) in vitro, however clinical data remains mixed. We reviewed a pilot protocol of BK prophylaxis with…
American Transplant Congress abstracts